Urinary Tract Infections, Pyelonephritis Acute, Intraabdominal Infections
Conditions
Brief summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous sulopenem and oral sulopenem etzadroxil/probenecid in adolescent patients.
Detailed description
After being informed about the study and potential risks, all patients giving written informed consent will be screened for eligibility. Hospitalized patients who are 12-18 years of age and who are receiving background antibiotic treatment for uncomplicated urinary tract infection, complicated urinary tract infection, acute pyelonephritis, or complicated intraabdominal infection, and who meet eligibility requirements will receive a single 1000 mg IV dose of sulopenem on Day 1. The following day, patients will receive a single dose of 500 mg of sulopenem etzadroxil and 500 mg of probenecid given orally as a bilayer tablet. During treatment, pharmacokinetic samples will be collected and patients will be monitored for safety and tolerability.
Interventions
DRUGSulopenem
sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
Sponsors
Iterum Therapeutics, International Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Patient's parent/both parents or guardian must provide written informed consent and a statement of assent from the adolescent patient (if required by Institutional Review Board \[IRB\] according to local regulations and guidelines) must be obtained prior to any study-related procedures. 2. Patient is male or female adolescent who are ≥12 and \<18 years of age. 3. Patient has a diagnosis of uUTI, cUTI, AP, or cIAI as documented by the treating physician 4. Patient will be hospitalized for urinary tract infection, acute pyelonephritis, or complicated intraabdominal infection for at least 48 hours and be receiving appropriate anti-infective treatment. 5. Patient must have sufficient venous access to permit administration of study drug, collection of PK samples, and monitoring of laboratory safety variables. 6. Female patients who are post-menarche must not be pregnant or breast feeding and must have a documented negative serum pregnancy test at Screening. 7. Post-menarchal females and post-pubertal males must agree to use a highly effective method of birth control with partners of childbearing potential throughout the duration of the study and for 1 month following the last dose of study drug. 8. Patient must be willing to follow all study procedures.
Exclusion criteria
1. Patient has creatinine clearance \<90 mL/min using the Cockcroft-Gault formula. 2. Patient is unable to tolerate oral medications. 3. Patient has presence of Endocarditis, Meningitis, Necrotizing fasciitis, or Gas gangrene 4. Patient has signs of severe sepsis 5. Patient has evidence of active liver disease or hepatic dysfunction 6. Patient has neutropenia with absolute neutrophil count \<500 cells/mm3. 7. Patient has history of solid organ transplantation reported at any time. 8. Patient has any finding that, in the view of the Investigator, would compromise the patient's safety requirements. 9. Patient has known allergies to penicillin, carbapenems, and/or cephalosporins, known allergy to probenecid, or severe allergic reactions to any drug in the past. 10. Patient has history of intolerance to β-lactam antibiotics, including but not limited to a history of clinically significant diarrhea/loose stools. 11. Patient has a history of hypersensitivity to the study drug or any of the excipients or to medicinal products with similar chemical structures. 12. Patient has involvement in the planning and/or conduct of this study 13. Patient has participated in any other clinical study where an investigational product was ingested within 30 days or 5 half-lives of the drug (whichever is longer) prior to the current study. 14. Patient has definite or suspected personal history or family history of clinically significant adverse drug reactions. 15. Patient has history or presence of GI, hepatic, or renal disease, or other conditions known to interfere with absorption, distribution, metabolism, or excretion of drugs. 16. Patient had treatment in the previous 3 months with any drug known to have a well-defined potential for hepatotoxicity (eg, halothane). 17. Patient weighs \<35 kg. 18. Patient is pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Maximum plasma concentration (Cmax) of sulopenem at multiple timepoints after dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time above minimum inhibitory concentration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Time above minimum inhibitory concentration (MIC) at multiple timepoints after dose |
| Area under the plasma concentration-time curve from time zero to time of last quantifiable plasma concentration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable plasma concentration at multiple timepoints after dose |
| Area under the plasma concentration-time curve from time zero extrapolated to infinity | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity at multiple timepoints after dose |
| Percentage of area under the concentration-time curve extrapolated | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Percentage of area under the concentration-time curve (AUC) extrapolated at multiple timepoints after dose |
| Time to maximum plasma concentration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Time to maximum plasma concentration (Tmax) of sulopenem at multiple timepoints after dose |
| Total body clearance for intravenous administration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Total body clearance for intravenous administration at multiple timepoints after intravenous dose |
| Apparent total body clearance for oral administration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Apparent total body clearance for oral administration at multiple timepoints after oral dose |
| Volume of distribution for intravenous administration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Volume of distribution for intravenous administration at multiple timepoints after intravenous dose |
| Apparent volume of distribution for oral administration | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Apparent volume of distribution for oral administration at multiple timepoints after oral dose |
| Terminal elimination half-life | To be measured at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 9.0, 10.0, and 12.0 hours post dose | Terminal elimination half-life at multiple timepoints after dose |
Countries
United States
Outcome results
None listed